FDA Issues Guidance to Improve Collection of Pregnancy Safety Data for Drugs and Biologics
FDA issued final guidance on postapproval pregnancy safety studies for drugs and biologics. While not directly targeting cosmetics, the guidance may influence future requirements for cosmetic products under MoCRA, especially regarding safety substantiation for pregnant populations.
Aforeworn detected this change in the Cosmetics & Personal-Care (MoCRA) space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Indie beauty brands, contract manufacturers, private-label makers, importers/distributors should confirm how it applies to their specific situation before acting. There is a time constraint attached: No immediate deadline; stay informed for future updates.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Cosmetics & Personal-Care (MoCRA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA released final guidance on methodologies for postapproval pregnancy safety studies for drugs and biologics.
Who it affects
Indie beauty brands, contract manufacturers, private-label makers, importers/distributors
What you must do
Monitor for any future MoCRA guidance that may incorporate similar pregnancy safety data requirements for cosmetics.
Deadline
No immediate deadline; stay informed for future updates.
Never miss a change like this again
Aforeworn watches Cosmetics & Personal-Care (MoCRA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Cosmetics & Personal-Care (MoCRA)
- FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight
- FDA Grants Seventh Approval under the National Priority Voucher Pilot Program
- FDA Expands AI Capabilities and Completes Data Platform Consolidation
- FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection
- FDA Warns Retailers Selling Illegal Tobacco Products That Look Like Everyday Products